About Us

Who We Are

The Johns Hopkins University Baltimore-India Clinical Trials Unit (JHUBI-CTU) is a collaboration and integration of 2 Clinical Research Sites (CRS’s):
 

The CTU supports clinical studies offered by 3 NIAID Clinical Research Networks

  1. AIDS Clinical Trials Group (ACTG)
  2. HIV Prevention Trials Network (HPTN)
  3. International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT)

The JHUBI-CTU works with patients at high risk for HIV and Hepatitis C in Baltimore and at one of the largest HIV/infectious diseases clinical care and clinical research units on the Indian subcontinent.

The CTU includes a highly experienced international leadership that is also uniquely positioned to make significant and strategic scientific contributions. 
 

Three Specific Aims

  1. Science. The CTU’s innovative Scientific Coordinating Committees bring together expertise in our strongest fields: Tuberculosis, Hepatitis, HIV Cure, HIV Prevention, Clinical Pharmacology, Pediatric & Adolescent Research, Inflammation & End-Organ Complications, Antibiotic Resistance, and Training & Mentorship.

    The Committees are highly creative in developing new study proposals, identifying and prioritizing studies for site implementation, and encouraging young and international investigators to contribute to novel scientific concepts valued by the networks we support.

  2. Populations. Our sites work with important and often under-represented populations.

    1. Impoverished urban African-Americans and other communities of color, those with a history of intravenous drug use and substance abuse in Baltimore 
    2. Vulnerable sexually active young urban MSM and women in Baltimore 
    3. Pregnant women, adolescents, and adults in urban India.


    Because both sites provide top-quality clinical care and clinical research at the same facility, we can efficiently identify potential research participants and rapidly enroll them into high priority research using our integrated clinical care and clinical research teams.

  3. Management. Our efficient and highly integrated administrative structure facilitates high quality clinical research while taking advantage of shared resources, investigator expertise and synergies among sites.

Clinical Trials

A5324: A Randomized, Double-Blinded, Placebo-Controlled...

ACTG A5324 is a phase IV randomized, double-blinded, placebo-controlled study to assess the efficacy of adding Maraviroc (MVC)...

Read More

A5207, Maintaining Options for Mothers Study (MOMS): A Phase...

A major disadvantage of giving SD NVP is the potential for maternal development of NVP resistance and additional resistance to...

Read More

A5253: Sensitivity and Specificity of Mycobacterium...

An estimated 3 million HIV-infected individuals will enter programs for antiretroviral (ARV) treatment in the coming year, with...

Read More

NWCS 445: Novel Biomarkers to Shorten TB Treatment

Objectives: Primary: To develop a highly predictive algorithm that identifies TB patients who will be cured by treatment...

Read More

P1108: A Phase I/II, Open-Label, Single Arm Study to...

This purpose of this study is to evaluate the pharmacokinetics (PK), safety, and tolerability of bedaquiline (BDQ) in...

Read More